Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hi, it’s Meghana. Lots happened this past weekend! We have news for you from the annual meeting of the American Association for Cancer Research, and also from the annual meeting of the American College of Cardiology. Interesting stuff.
WHO scientists question Grail endpoint for multi-cancer test
A team of WHO scientists are questioning Grail’s approach to evaluating the efficacy of its multi-cancer early detection test, Galleri. The company is in the midst of two very large studies to determine how beneficial the test is — evaluating it in a 140,000-person trial with the U.K.’s National Health Service, and a 50,000-patient study among Medicare enrollees in the U.S. The studies are both examining how many patients given the test are diagnosed with late-stage cancer, compared to a control group that doesn’t take the test.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect